Supplementary Material for: Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study

Background: Clinicians providing dialysis care have numerous erythropoiesis-stimulating agents (ESAs) available for treating anemia. We sought to provide a contemporary description of ESA types used in hemodialysis (HD) settings in nine European countries. Methods: Our study uses Dialysis Outcomes and Practice Patterns Study phase 5 (2012–2015) data from nine European countries (Belgium, France, ­Germany, Italy, Russia, Spain, Sweden, Turkey, and the United Kingdom). A total of 164 facilities and 3,281 patients contributed cross-sectional data. ESA types captured included short-acting epoetins (e.g., epoetin alfa, beta, etc., including biosimilars), darbepoetin alfa, and continuous erythropoietin receptor agonist (CERA; methoxy polyethylene glycol-epoetin beta). Results: We observed broad variability across countries in prescription of ESA types: prescription of epoetin alfa or epoetin beta ranged from 22% (France) to 78% (Russia), darbepoetin alfa prescription ranged from 13% (Russia) to 53% (UK), and CERA prescription ranged from Conclusion: A variety of short- and long-acting ESAs are commonly used in European HD facilities to maintain hemoglobin at remarkably similar levels with each ESA type. The availability of numerous ESA options for managing anemia has allowed European providers to optimize anemia management according to the particular circumstances of each patient.背景：提供透析诊疗服务的临床医师可选用多种促红细胞生成素刺激剂（erythropoiesis-stimulating agents, ESAs）治疗贫血。本研究旨在阐述欧洲9个国家血液透析（hemodialysis, HD）场景中各类ESA的当前应用情况。 方法：本研究采用透析结局与实践模式研究第5期（2012—2015年）的数据，数据来自欧洲9个国家（比利时、法国、德国、意大利、俄罗斯、西班牙、瑞典、土耳其及英国），共计164家医疗机构与3281名患者贡献了横断面研究数据。本研究纳入的ESA类药物包括短效促红细胞生成素（如依泊汀α、依泊汀β等，含生物类似药）、达贝泊汀α，以及连续红细胞生成素受体激动剂（continuous erythropoietin receptor agonist, CERA；甲氧基聚乙二醇-依泊汀β）。 结果：本研究观察到不同国家间的ESA类药物处方存在显著差异：依泊汀α或依泊汀β的处方占比范围为22%（法国）至78%（俄罗斯），达贝泊汀α的处方占比范围为13%（俄罗斯）至53%（英国），而CERA的处方占比范围为 结论：欧洲血液透析中心普遍使用多种短效及长效ESA类药物，且各类ESA均可将血红蛋白维持在近乎一致的水平。多种ESA治疗方案的可及性，使得欧洲医疗服务提供者能够根据每位患者的具体情况优化贫血管理策略。